Asia

Huawei and Philips announced a China cloud healthcare partnership that uses AI to deliver best diagnostic practices and monitoring in second tier China cities. The partnership combines Huawei’s IT capability with Phillips’ knowledge of diagnostic scanning devices.
Takeda is jumping into the $40B market for NASH and other diseases of the liver with a $470M+ investment into HemoShear Therapeutics.
Suzhou’s Innovent Biologics will use a proprietary H2L2 transgenic mouse platform owned by Harbour Biomed of Shanghai to discover new mAbs.
What are the risks and benefits of taking such a step? And what factors are important to consider before doing so?
PRESS RELEASES